secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001654954-24-010666
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica reports record FY2023 revenue $25.2M (+33% YoY); net loss $34.5M; guides FY2024 $31-35M
--------------------------------------------------------------------------------

- Q4 2023 revenue $7.3M (+19% YoY); FY2023 revenue $25.2M (+33% YoY), driven by Diagnostics (+252%) and Therapeutic Devices (+28%).
- Gross margin 69% for FY2023; consumable revenue $16.4M (+41% YoY), 65% of total revenue.
- Net loss $34.5M ($0.035/share) vs $17.0M in FY2022; Adjusted Non-GAAP EBITDA loss $12.8M.
- Cash and securities $100.5M at Dec 31, 2023; reiterated FY2024 revenue guidance $31-35M.
- Acquisitions of SMP (VetGuardian) and Qorvo Biotechnologies in 2023; launched TRUVIEW and new assays.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495424010666/0001654954-24-010666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495424010666/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-010666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer